Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Differences in epidemiology of candidaemia in the Nordic countries - what is to blame?

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Would you like to purchase a rodent with dermatophytes?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Black yeast-like fungi in skin and nail: it probably matters

    Research output: Contribution to journalReviewResearchpeer-review

  1. Would you like to purchase a rodent with dermatophytes?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pediatric Candidemia Epidemiology and Morbidities: A Nationwide Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Implications of the EUCAST Trailing Phenomenon in Candida tropicalis for the In Vivo Susceptibility in Invertebrate and Murine Models

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Liv Hesstvedt
  • Maiken C Arendrup
  • Eira Poikonen
  • Lena Klingpor
  • Vanda Friman
  • Ingvild Nordøy
  • Swedish fungal Surveillance Group Collaborators (16)
View graph of relations

National data from Denmark, Finland, Norway and Sweden demonstrate remarkable differences in candidaemia epidemiology. Only Denmark has reported a high incidence of 10 per 100 000 inhabitants and a species shift towards increased C. glabrata candidaemias. The reasons for this development remain unclear. The aim of this study was to explore possible contributing factors for the differences in Candida epidemiology in the Nordic countries. We used public data from 2011 from Denmark, Finland, Norway and Sweden on epidemiology, demographics, health facilities, predisposing risk factors, consumption of antimicrobial drugs and fungicides in agricultural industry. Only the prevalence of haematological malignancies (P < 0.001) was significantly higher in Denmark compared to the other Nordic countries. The antibacterial drug use of metronidazole, piperacillin-tazobactam, ciprofloxacin, colistin and carbapenems, and antifungal use of fluconazole in humans (P < 0.001), were significantly higher in Denmark compared to the other Nordic countries (all P < 0.001). Our findings suggest haematological malignancy, the use of certain antibacterial drugs and azoles in humans as possible contributing factors for the differences in Candida epidemiology. However, our results should be interpreted with caution due to the lack of long-term, case-specific data. Further studies are needed.

Original languageEnglish
JournalMycoses
Volume60
Issue number1
Pages (from-to)11-19
Number of pages9
ISSN0933-7407
DOIs
Publication statusPublished - Jan 2017

    Research areas

  • Journal Article

ID: 52705313